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Crohn’s disease (CD) is a chronic inflamma­
tory disorder, primarily affecting the gastro­
intestinal tract. It arises through an aberrant 
interaction between the bowel contents and 
the immune system, although the mechanistic 
basis of disease pathogenesis remains poorly 
understood. To date, numerous hypotheses 
have been proposed including atypical infec­
tion, the presence of abnormal particulate ma­
terial within the bowel, and autoimmunity 
(Marks and Segal, 2008). Most current theories 
center on disordered T lymphocyte activation 
(Xavier and Podolsky, 2007). Although T lym­
phocytes are important in the induction and 
maintenance of the chronic inflammatory phase, 
their involvement in the induction of CD le­
sions remains unproven.
Recent genome­wide association studies 
(GWAS) have generated considerable inter­
est after the identification of >30 polymor­
phisms  that  increase  susceptibility  to  CD 
(Wellcome Trust Case Control Consortium, 
2007; Barrett et al., 2008). Several of these 
refocus attention on the innate immune system. 
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The cause of Crohn’s disease (CD) remains poorly understood. Counterintuitively, these 
patients possess an impaired acute inflammatory response, which could result in delayed 
clearance of bacteria penetrating the lining of the bowel and predispose to granuloma 
formation and chronicity. We tested this hypothesis in human subjects by monitoring 
responses to killed Escherichia coli injected subcutaneously into the forearm. Accumulation 
of 111In-labeled neutrophils at these sites and clearance of 32P-labeled bacteria from them 
were markedly impaired in CD. Locally increased blood flow and bacterial clearance were 
dependent on the numbers of bacteria injected. Secretion of proinflammatory cytokines by 
CD macrophages was grossly impaired in response to E. coli or specific Toll-like receptor 
agonists. Despite normal levels and stability of cytokine messenger RNA, intracellular levels 
of tumor necrosis factor (TNF) were abnormally low in CD macrophages. Coupled with 
reduced secretion, these findings indicate accelerated intracellular breakdown. Differential 
transcription profiles identified disease-specific genes, notably including those encoding 
proteins involved in vesicle trafficking. Intracellular destruction of TNF was decreased by 
inhibitors of lysosomal function. Together, our findings suggest that in CD macrophages, an 
abnormal proportion of cytokines are routed to lysosomes and degraded rather than being 
released through the normal secretory pathway.
© 2009 Smith et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Figure 1.  Neutrophil accumulation and subsequent clearance of E. coli from the tissues is markedly delayed in a dose-dependent manner in CD.  
111Indium-labeled autologous neutrophils were injected intravenously at the same time as killed E. coli were injected subcutaneously into each forearm.  
(a) Radioactivity measured over the injection sites showed a much smaller proportion of labeled cells accumulating in CD subjects. (b) -Camera image of 
a CD patient at 24 h after injection, demonstrating focal accumulations of radioactivity at bacterial injection sites (arrows) and confirming lack of bowel JEM VOL. 206, August 31, 2009 
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inflammation. (c) 32P-labeled killed E. coli were injected into the subcutaneous tissues of the forearm and radioactivity was measured at the skin surface. 
Clearance of radioactivity was much slower in CD than in HC or UC. Extrapolating these curves indicated that almost complete removal (99%) would take 
10.2 and 7.1 d in HC and UC subjects, respectively, compared with 44.3 d in CD. (d and e) Effect of increasing bacterial dose from 105 to 108 on blood flow 
at injection site (d) and bacterial clearance (e). The numbers of subjects studied in the dose response experiment are depicted in e. All results are expressed 
as mean ± SEM (**, P < 0.01; ***, P < 0.001).
 
The CARD15 (caspase-recruitment domain 15) gene remains 
the best studied and encodes a pathogen­recognition pro­
tein primarily expressed within phagocytes (Hugot et al., 
2001; Ogura et al., 2001). Its product, NOD2, responds to 
bacteria­derived peptidoglycan by stimulating proinflam­
matory cytokine release, a function attenuated by the de­
scribed  polymorphisms.  Other  significantly  replicated 
associations include the ATG16L1 and IRGM genes cod­
ing for proteins involved in autophagy.
Although these associations are highly significant when 
comparing very large population groups and are valuable in 
providing an indication of cellular processes and pathways 
involved in CD pathogenesis, the effect sizes at any individ­
ual locus are weak (the majority incurring odds ratios <1.6), 
and polymorphisms are common in healthy control (HC) 
subjects. For example, the incidence of one or two CD­ 
related mutations in the gene for NOD2 in the general popu­
lation is 15 and 0.5%, respectively, whereas in CD the figures 
are 28 and 8% (Cuthbert et al., 2002; Hugot et al., 2007). 
However, only 1 in 1,000 of the population develop CD, 
which means that in a general population of 100,000 individ­
uals, roughly 15,000 will have one relevant mutation and 500 
will  have  two  such  mutations.  This  population  will  have 
100 cases of CD, in whom there will only be 28 single and 
8 double mutations on the NOD2 gene. The numbers are 
even  more  dramatic  when  examining  mutations  at  the 
ATG16L1 (autophagy) locus with 27,000 of the general pop­
ulation having the GG CD­related genotype as compared 
with 37 patients (Hampe et al., 2007). GWASs have been in­
formative but have failed to explain the cause of the diseases 
under investigation (Donnelly, 2008). All 32 CD­associated 
genes combined have been calculated to contribute <20% of 
the heritable risk (Barrett et al., 2008), leading to the concept 
of the “missing heritability” (Maher, 2008).
It was realized >30 yr ago that the acute inflammatory re­
sponse in respect to neutrophil recruitment was defective in 
CD (Segal and Loewi, 1976). More recently, we have docu­
mented defective neutrophil accumulation and cytokine lev­
els at sites of intestinal and skin trauma (Marks et al., 2006). 
These defects in acute inflammation were independent of the 
CARD15 genotype. Further investigation demonstrated re­
duced blood flow in the skin upon bacterial challenge that 
could be partially corrected by the administration of sildena­
fil. We concluded that a general phenotypic abnormality can 
be revealed in CD when the innate immune system is stressed 
in vivo, namely that acute inflammation is generally and se­
verely impaired. We propose that the consequence of a weak 
initial reaction to the ingress of gut bacteria into the tissues 
would be their defective removal and that this persistence 
could drive secondary chronic inflammation. A unique set of 
experiments were performed to test this hypothesis directly 
by measuring the accumulation of neutrophils and clearance 
of bacteria from the tissues of CD patients. In addition, in vitro 
studies were performed using monocyte­derived macro­
phages to identify a defective mechanism, which could ex­
plain the diminished acute inflammatory response in CD 
patients. In the absence of a single causative gene and, hence, 
an accurate animal model of CD, these experiments had to be 
conducted on human subjects.
RESULTS
Neutrophil recruitment to sites of bacterial injection
We first determined whether the previously observed im­
paired recruitment of neutrophils to sites of local trauma in 
CD extended to the inflammation induced by bacteria in the 
tissues (Segal and Loewi, 1976; Marks et al., 2006). Autologous 
neutrophils were labeled with 111indium (Segal et al., 1981) 
and injected intravenously at the same time as Escherichia coli 
were inoculated into the volar aspect of each forearm in HC 
(n = 6) and CD (n = 5) subjects. The labeled neutrophils ac­
cumulated at the sites of bacterial injection (Fig. 1 a) in addi­
tion to the previously described distribution to the spleen, 
liver, and bone marrow (Fig. 1 b).
In HC subjects, significant cellular recruitment could be 
measured at 4 h (889 ± 53 cpm; n = 6), and this increased 
over a 24­h period (1,738 ± 98 cpm; n = 6), at which time 
0.17 ± 0.014% of the injected dose of radioactivity was 
present at each injection site (Fig. 1 a). Assuming a whole 
body pool of roughly 1011 neutrophils (Cartwright et al., 
1964), this represents 108 cells to deal with the 3 × 107 bac­
teria injected. The results were very different in CD subjects 
(P < 0.0001; Fig. 1 a), with less than one­third of the normal 
numbers of neutrophils accumulating at 4 h (290 ± 52 cpm; 
n = 5) and 24 h (555 ± 78 cpm; n = 5).
Clearance of 32P-labeled E. coli
A functional consequence of reduced neutrophil influx was 
assessed by measuring the clearance of 32P­labeled E. coli from 
the forearm in HC (n = 16), CD (n = 14), and ulcerative coli­
tis (UC; n = 3) subjects. Immediately after inoculation, surface 
counts at each injection site were 2,688 ± 160 cpm (mean ± 
SEM). In all groups, clearance followed biphasic nonexpo­
nential kinetics, with a rapid initial phase followed by a slower 
secondary phase (Fig. 1 c). An overall test for equality demon­
strated that clearance curves for HC and CD subjects were 
significantly different (P = 9 × 106), with a marked delay in 
CD compared with HC. UC subjects demonstrated clearance 
profiles similar to those of HC. Extrapolating clearance curves 1886 INFLAMMATION AND MACROPHAGES IN CROHN’S | Smith et al.
amined the influence of NOD2 status on TNF secretion by 
macrophages in response to TLR2 or TLR4 agonists. The pres­
ence of one or two CD­associated mutations in the NOD2 
gene had no effect on TNF secretion (Fig. S2 b).
Differences  in  monocyte/macrophage  populations  and 
maturation were investigated in the three groups (Fig. S3). 
The initial M1 (CD14+/CD16) and M2 (CD14+/CD16+) 
monocyte population were similar in the all three groups, as 
were messenger RNA (mRNA) levels of the macrophage 
maturation markers F4/80, L­selectin, and ICAM­1 after in 
vitro differentiation.
Macrophage mRNA transcription profiles
To account for impaired cytokine secretion, we examined 
global transcription profiles of macrophages. RNA was exam­
ined from macrophages from HC (n = 26), ileal (n = 10), co­
lonic CD (n = 16), and UC (n = 20) subjects, before and after 
exposure to HkEc. The proinflammatory cytokines GM­CSF, 
IL­6, IFN­, and TNF, which had demonstrated diminished 
secretion, were tested by quantitative PCR and found to have 
mRNA levels equivalent to those of HC after HkEc stimula­
tion (Table S1). However, disease­specific changes were ob­
served and are presented in Fig. 3. A four­way Venn diagram 
shows the numbers of probe sets differing in expression level 
(P < 0.01 and fold change >1.2) before and after stimulation 
between either group of CD patients and HC subjects (Fig. 3 a). 
Significant changes from HC levels were observed in the ex­
pression of hundreds of genes in the different groups, which 
were internally consistent. Surprisingly little overlap was ob­
served between profiles of HkEc­stimulated macrophages in 
ileal and colonic CD.
The identities of the differentially regulated genes com­
mon to ileal and colonic CD, and the cellular processes in 
which they are involved, are shown in Fig. 3 (d and i). The 
27 probe sets represent 18 genes of known function. Of these, 
nine have previously been reported as participating in vesicle 
trafficking and cytoskeletal organization, suggesting that the 
problem may lie in the posttranscriptional processing, stor­
age, or secretion of cytokines. The data were also analyzed by 
determining the most significantly induced or repressed genes 
in individual groups, with false discovery rate (FDR) correc­
tion applied. These gave similar results to those shown in Fig. 3 
(Fig. S4; Tables S2 and S3), demonstrating an overrepresen­
tation of genes involved in vesicle trafficking and cytoskel­
etal organization.
To control for nonspecific effects resulting from chronic 
bowel  inflammation,  we  conducted  similar  analyses  on 
macrophages from UC patients. In UC, a total of 354 and 
554 probe sets differed from HC, before and after HkEc 
stimulation, respectively. There was very little overlap be­
tween differentially expressed genes in CD and UC (Fig. 3, 
b and c). Of those genes common to both, a relatively large 
proportion was also involved in vesicle trafficking and cy­
toskeletal organization, as well as RNA metabolism and 
cellular signaling (Fig. 3 d, ii­iv). However, although most 
of the differentially expressed genes common to both CD 
to a point where 99% of inoculated material would have been 
cleared gave total clearance times of 10.2 d (95% confidence 
interval: 8.3–13 d) in HC, 7.1 d (5.4–10.4 d) in UC, and 44.3 d 
(21.8– d) in CD. Patients were subdivided into those with 
ileal or colonic involvement, as CD is a syndrome with both 
clinical and genetic evidence to suggest that precise patho­
genic mechanisms operating in each region of the bowel may 
differ. Clearance appeared to be faster in the ileal (n = 5) than 
in the colonic (n = 9) CD subjects, but the differences were 
not statistically significant (Fig. S1 a). In addition, the presence 
of CD­associated mutations in CARD15 had no effect on 
bacterial clearance (Fig. S1 b).
The numbers of bacteria injected had an important effect 
on local blood flow and bacterial clearance. In HC subjects, 
blood flow increased about sevenfold between doses of 105 
and 108 organisms (Fig. 1 d). Blood flow levels in CD patients 
were similar to those in HC between dosages of 105 and 107 
bacteria. Doses >3 × 107 resulted in significantly reduced 
blood flow in CD subjects, with levels approximately half 
those recorded for HC. Bacterial clearance was dramatically 
different between the two groups (Fig. 1 e). In HC subjects, 
clearance rates were relatively stable between 105 and 3 × 107 
organisms and actually increased at the highest dose, whereas 
in CD, although it was normal at 105 and 106, there was a 
dramatic and highly significant (P < 0.0001) drop in clearance 
at and above 107 bacteria.
Macrophage cytokine secretion
Dramatic differences were observed in the secretion of a panel 
of inflammation­related cytokines and chemokines by periph­
eral blood monocyte­derived macrophages after 24 h of stim­
ulation with heat­killed E. coli (HkEc; Fig. 2). We observed 
distinct profiles in patients with ileal and colonic CD. The 
proinflammatory cytokines TNF, IL­4, IL­5, IL­13, IL­15, 
and IFN­ were reduced in all CD patients, whereas IL­6, 
IL­12(p70), G­CSF, and GM­CSF were only low in colonic 
CD and IL­17 was only low in ileal CD. Direct comparisons 
between  macrophages  from  ileal  and  colonic  CD  subjects 
identified IL­6, IFN­, and G­CSF as significantly different 
between the two phenotypes. All three were released at lower 
levels by colonic compared with ileal CD macrophages. In 
contrast, macrophages from patients with UC secreted proin­
flammatory cytokines at levels similar to, or greater than, HC 
subjects. All patients released normal levels of the antiinflam­
matory  cytokines  IL­1Ra  and  IL­10  and  the  chemokines 
RANTES, IP­10, MCP­1, and IL­8.
In addition, we examined the secretion of IL­5, IL­6, IL­10, 
IL­17, GM­CSF, MCP­1, and IP­10 at 24 h by macro­
phages after stimulation with the TLR2 ligand Pam3CSK4. 
Secretion of IL­5 and GM­CSF were both reduced irrespec­
tive of CD phenotype, whereas secretion of IL­6 and IL­17 
were low from patient macrophages with colonic or ileal 
CD, respectively (Fig. S2 a). Previously, we have extensively 
studied CD patients with NOD2 mutations using muramyl 
dipeptide and reported transcription profile and cytokine se­
cretion abnormalities (Marks et al., 2006). We have now ex­JEM VOL. 206, August 31, 2009 
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lighting the fact that UC and CD are distinct diseases, pos­
sibly at opposite ends of the inflammatory response (Marks 
and Segal, 2008).
groups were similarly up­ or down­regulated in compari­
son with HC (Fig. 3 d, i), the majority of those common to 
UC and CD changed reciprocally (Fig. 3 d, ii­iv), high­
Figure 2.  Proinflammatory cytokine secretion by macrophages from CD patients is deficient in response to E. coli. Supernatants from macro-
phages stimulated for 24 h with HkEc were tested for the levels of cytokines and chemokines. (a) Macrophages from HC subjects released varying 
amounts of cytokines and chemokines after HkEc stimulation. (b) Cytokine and chemokine release expressed as a percentage of that secreted by HC cells 
(blue bar) from ileal and colonic CD patients. The numbers of subjects in each group are shown on left; each patient was used once. All results are ex-
pressed as mean ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001).1888 INFLAMMATION AND MACROPHAGES IN CROHN’S | Smith et al.
scription occurred in CD (n = 7) and HC (n = 8) macro­
phages after HkEc stimulation at equivalent levels (Fig. 4 a). 
TNF mRNA stability was determined using actinomycin­d 
(an inhibitor of RNA polymerase) and was identical between 
HC and CD macrophages after HkEc stimulation (Fig. 4 b).
Cell lysates were prepared from macrophages from HC   
(n = 6) and colonic CD (n = 6) subjects, and intracellular TNF 
was quantitated by Western blotting (Fig. 4, c and d). The 
level of intracellular TNF in HkEc­stimulated macrophages 
was lower in CD (P < 0.05) than HC (Fig. 4, c and d). The 
Transcription, translation, and secretion of cytokines  
by macrophages
Our observations of diminished proinflammatory cytokine 
secretion, equivalent cytokine steady­state mRNA levels, 
and a high proportion of abnormally expressed genes associ­
ated with vesicle trafficking and cytoskeletal organization in 
CD led us to investigate further aspects of RNA metabolism 
and intracellular protein handling. Cytokine transcriptional 
activation  was  investigated  using  macrophages  transfected 
with a TNF promoter–luciferase reporter. TNF gene tran­
Figure 3.  Abnormal transcriptional profiles of CD macrophages on Affymetrix gene arrays. (a) Venn diagram shows the number of probe sets dif-
fering in expression (P < 0.01) between ileal and colonic CD versus HC macrophages in the unstimulated state and after exposure to HkEc. (b and c) As in a, 
but comparing differentially expressed probe sets between ileal and colonic CD and UC versus HC in unstimulated (b) and HkEc-stimulated (c) cells. (d) i-iv 
designate overlaps of differentially expressed genes of known function after HkEc stimulation between disease groups, as labeled in Venn diagrams.JEM VOL. 206, August 31, 2009 
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Figure 4.  Intracellular levels of TNF are lower in CD, despite normal transcription and mRNA stability, but restored to normal in the pres-
ence of Bref-A and lysosome inhibitors. (a) Macrophages transfected with an adenoviral vector containing a TNF promoter and luciferase reporter 
demonstrated equivalent TNF transcription levels in HC (n = 8) and CD (n = 7) subjects. (b) TNF mRNA stability is comparable in HC and CD macrophages 
after stimulation with HkEc. (c) Intracellular levels of TNF after HkEc stimulation with or without Bref-A were determined by Western blotting. (d) CD con-
tained significantly lower levels of intracellular TNF than HC macrophages after HkEc stimulation but returned to normal levels with the inclusion of Bref-
A (n = 6 in all groups). (e) Intracellular levels of TNF after HkEc stimulation with or without lysosomal inhibitors were determined by Western blotting.  
(f) Inhibitors of lysosomal proteolysis increase intracellular TNF levels in HC and CD macrophages (n = 4 in all groups; gray line denotes level of HkEc 
alone). Significance levels are compared with HkEc alone. All patients in these studies had colonic CD and subjects were used once per assay. Results are 
shown as mean ± SEM (*, P < 0.05).1890 INFLAMMATION AND MACROPHAGES IN CROHN’S | Smith et al.
Figure 5.  Intracellular levels of chemokines and cytokines after HkEc stimulation in the presence of vesicle trafficking and lysosomal inhibi-
tors. (a) Intracellular cytokine array profiles obtained from macrophages stimulated with HkEc in the presence of absence of either Bref-A or monensin.  JEM VOL. 206, August 31, 2009 
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(b) Cytokine array map. (c) Various chemokines and cytokines demonstrate reduced intracellular levels in CD macrophages after HkEc stimulation and are 
either normalized or elevated after Bref-A or monensin treatment (n = 4 in all groups). All patients studied had colonic CD and subjects were used once 
per assay. Results shown are mean ± SEM (*, P < 0.05; ***, P < 0.001).
 
inclusion of brefeldin A (Bref­A), a potent inhibitor of ER­to­
Golgi protein transport during macrophage HkEc stimula­
tion resulted in approximately equivalent levels of intracellular 
TNF in both CD and HC (Fig. 4, c and d). The results ob­
tained with Bref­A demonstrated that TNF translation occurs 
normally in CD macrophages.
We investigated the role of the lysosome in intracellular 
cytokine trafficking with the inclusion of monensin, NH4Cl, 
or chloroquine during macrophage HkEc stimulation. NH4Cl 
and chloroquine partition into acidic compartments and ele­
vate the pH, whereas monensin is a proton ionophore with 
similar but more potent effects. In HkEc­stimulated macro­
phages from colonic CD patients (n = 4), all three inhibitors 
of lysosomal function increased intracellular levels of TNF by 
between twofold and sevenfold (Fig. 4, e and f). Incubating 
macrophages  with  the  proteosome  inhibitor  MG132  was 
without effect (unpublished data).
In addition to TNF, the intracellular levels of GRO­, 
IL­1­, IL­6, MIP­1, and MIP­1 were also depressed in 
CD macrophages after HkEc stimulation (Fig. 5). The inclu­
sion of Bref­A resulted in the normalization of intracellular 
levels of all the cytokines and chemokines tested (Fig. 5,   
a and c). In comparison, monensin either normalized the in­
tracellular levels (IL­1, IL­6, and MIP­1) or resulted in a 
significant elevation compared with HC (n = 4; GRO­ and 
MIP­1; Fig. 5, a and c).
DISCUSSION
In contrast to the relatively weak genetic effects identified in 
the GWAS (Wellcome Trust Case Control Consortium, 2007), 
a common major phenotypic abnormality becomes apparent 
in CD when the innate immune system is stressed in vivo. 
This is the result of a severely impaired acute inflammatory 
response in these individuals (Marks et al., 2006). We have 
suggested that the intensity of the inflammatory response in 
the whole population follows a normal Gaussian distribution. 
Individuals at the extreme lower tail of this spectrum, as a 
consequence of the additive effect of many gene variants, are 
at risk of CD. NOD2, and potentially other systems, provide 
a compensatory boost to acute inflammation, which is pro­
tective in this setting (Marks and Segal, 2008).
These studies provide the first demonstration in CD that 
there is a profound defect in the recruitment of neutrophils 
after the introduction of E. coli into the tissues and that the 
subsequent clearance of these organisms is grossly delayed in 
this condition. This bacterium was used in these studies be­
cause it is the major aerobic component of the bowel flora 
and present in those regions of the gut affected by CD (Fine­
gold, 1969). E. coli have been implicated in the pathogenesis 
of CD (Rhodes, 2007), have been found within macrophages 
in Crohn’s tissue (Liu et al., 1995), and have also been cul­
tured from draining mesenteric lymph nodes (Ambrose et al., 
1984b). Granulomas removed from CD tissue have been 
shown by PCR to contain E. coli DNA (Ryan et al., 2004), 
and an ileal CD E. coli isolate (LF82) was capable of inducing 
granuloma formation in vitro (Meconi et al., 2007). In addi­
tion, we had previously shown that there was an important 
abnormality of acute inflammation in response to E. coli in 
CD (Marks et al., 2006).
The observed abnormalities in CD did not occur as a 
consequence of the inflammatory process, drug therapy, or 
bowel ulceration. All the patients were in remission and most 
were not on therapy, with a minority receiving 5­aminosali­
cylic acid–containing drugs. Bacterial clearance was normal 
in the control group of subjects with UC, who were also in 
remission and on 5­aminosalicylic acid or no treatment.
The rate at which neutrophils accumulate at sites of bacte­
rial ingress into the tissues is crucial to the final outcome. It has 
previously been demonstrated that in a three­dimensional tis­
sue matrix, bacterial phagocytosis is directly related to neutro­
phil numbers (Li et al., 2004). In the absence of adequate 
neutrophil recruitment, monocytes and macrophages might 
function in a containing role, such that material remaining after 
inoculation is surrounded and only slowly degraded (Issekutz 
et al., 1981). This is supported by the recovery of bacterial 
products from Crohn’s granulomata (Ryan et al., 2004).
The consequence of the delayed neutrophil accumulation 
is that foreign fecal material is not cleared adequately from 
the tissues, leading to granulomatous inflammation. Congen­
ital monogenic innate immunodeficiencies, in which neutro­
phil  dysfunction  predominates,  frequently  manifest  bowel 
inflammation  that  is  indistinguishable  from  CD  (Rahman   
et al., 2008). These disorders are also associated with major 
defects in the clearance of foreign material caused by failure 
of neutrophils to accumulate in sufficient numbers (congeni­
tal neutropenias and leukocyte adhesion deficiency), poor di­
gestion within excessively acidic phagolysosomes (chronic 
granulomatous disease and glycogen storage disease­1b), and 
impaired vesicle trafficking and fusion of the granules and 
phagosomes (Chediak­Higashi and Hermansky­Pudlak syn­
dromes). The genes underlying these disorders have not been 
detected by GWAS of CD because of their extreme rarity.
In the absence of a monogenic lesion in the immune sys­
tem, CD patients might also be unduly susceptible to bacterial 
infection, although the necessary large­scale studies have not 
been performed (Kyle, 1980; Ambrose et al., 1984a; Kaplan 
et al., 2007). It becomes more difficult to assess the incidence 
of disease­specific infection once a diagnosis of CD has been 
made because of confounding factors including surgery, mal­
nutrition, immunosuppressant therapy, and bowel­related 
complications such as abscesses and fistulae. Another consid­
eration is bacterial load. Most acute infections originate from 1892 INFLAMMATION AND MACROPHAGES IN CROHN’S | Smith et al.
cretion of a panel of inflammatory cytokines and chemokines 
by macrophages in response to stimulation with E. coli or 
TLR ligands and observed the production of dramatically 
low levels of proinflammatory cytokines in cells from CD 
patients. In our previous study, we found local levels of IL­8 
and IL­1 to be low after trauma to the skin and bowel 
(Marks et al., 2006). In the current study, we have found that 
macrophages secrete normal amounts of IL­8 after stimula­
tion with bacteria. This discrepancy between tissue levels and 
isolated macrophages in response to E. coli could lie in the 
type of cells producing IL­8 in skin windows and bowel bi­
opsies, and/or in a different agonist. Neutrophils themselves 
produce copious amounts of IL­8 and IL­1, so the lower 
levels in skin windows and bowel biopsies in CD are consis­
tent with the reduced recruitment at these sites (Fujishima   
et al., 1993; Greten et al., 2007). In the study by Marks et al. 
(2006), the release of IL­8 by macrophages from CD patients 
was diminished after stimulation with wound fluid, TNF, and 
C5a but unaltered after stimulation with the TLR4 ligand li­
popolysaccaride. IL­8 release is normal after bacterial stimula­
tion (whole E. coli as well as TLR2 stimulation), so the lower 
levels in the in vivo study could be the result of activation of 
macrophages by nonmicrobial agonists.
To explain the cause of impaired cytokine secretion by 
macrophages from CD patients, we examined the profiles of 
RNA expression against a chip containing fragments of genes 
representing the whole human transcriptome. The first im­
portant observation was that macrophages from patients with 
colonic or ileal CD and UC exhibited distinct expression 
profiles when compared with HC, identifying these as three 
separate disease clusters. Second, levels of mRNA encoding 
proinflammatory cytokines were normal in unstimulated and 
HkEc stimulated macrophages, providing evidence that the 
defective secretion was not at the level of gene transcription.
A possible mechanism responsible for diminished proin­
flammatory cytokine release was provided by examining the 
abnormally expressed genes common to both types of CD 
after HkEc stimulation. Approximately half of the genes had 
some association with cellular secretory systems, suggesting 
that impaired macrophage secretion is responsible for the di­
minished proinflammatory cytokine release. The failure of a 
secretory system would provide a generic mechanism for the 
impaired  release  of  several  functionally  related  cytokines. 
Hermansky­Pudlak syndrome and Chediak­Higashi disease, 
both of which are associated with noninfectious granuloma­
tous enterocolitis, are the result of primary abnormalities in 
the cytoskeletal transport of vesicles (Rahman et al., 2008). 
These findings are particularly compelling given the recent 
descriptions of variants in autophagy genes which are associ­
ated with CD susceptibility (Hampe et al., 2007; Parkes et al., 
2007; Rioux et al., 2007). Autophagy involves vesicle traf­
ficking in the formation of double­membrane vesicles that 
deliver cytoplasmic material to the lysosomes (Levine and 
Deretic, 2007). Additionally, autophagy is required to kill 
and remove intracellular organisms in macrophages, so its 
dysfunction is consistent with the theme we have developed: 
a  small  number  of  inoculating  organisms,  which  even  the 
dampened immunity in CD appears to be able to control. Our 
findings of the relationship between bacterial dose and clear­
ance are important in this respect because they demonstrate 
that CD patients can deal efficiently with small numbers of or­
ganisms in the tissues but that the clearance mechanisms are 
overwhelmed by a large bolus of bacteria. CD occurs almost 
exclusively in the terminal ileum and colon, which respec­
tively contain 108 and 1011 bacteria/ml, higher than the   
105 bacteria/ml or less in other regions of the small bowel   
(Farthing, 2004). Reflux through the ileocaecal valve carries 
caecal contents into the terminal ileum, elevating the micro­
bial levels in this region (Malbert, 2005). After surgery, recur­
rence is seen in 80% of cases, and where small bowel has 
been resected, recurrence generally occurs in the small bowel 
just proximal to the anastomosis. This indicates that recurrence 
is highly dependent on the proximity to the large bowel con­
tents rather than a specific abnormality associated with the   
terminal ileum (Cameron et al., 1992). Therefore, the large 
bowel and adjacent ileum provide a unique environment in 
the body that contains a massive bacterial load, which can gain 
instant access to the tissues if the mucosal barrier is breeched.
The detrimental effect of fecal content in the tissue might 
not primarily result from the infectious nature of the organ­
isms, as many are not particularly virulent, but by the quan­
tity of organic material that must be removed before resolution 
can occur. Difficulty in clearing exogenous organic material 
could also account for the false­positive results in CD to Kveim 
tests, which were conducted to diagnose sarcoidosis by in­
jecting a preparation of the spleen of a patient into the skin, 
which was subsequently examined for a granulomatous re­
sponse (Mitchell, 1971).
Clearly, the retention of fecal material in the tissues of the 
wall of the bowel will have major local and systemic inflamma­
tory, immunological, and constitutional consequences. Many 
of the immunological studies conducted on Crohn’s patients, 
such as those implicating adaptive immunity in local tissue 
damage (Xavier and Podolsky, 2007), might be measuring sec­
ondary immunological responses to this foreign material.
We then turned our attention to identifying the mecha­
nism underlying impaired neutrophil accumulation. CD is 
caused by the complex interplay of many genes coupled with 
bacterial exposure, which makes it difficult, if not impossible, 
to identify specific molecular lesions common to these pa­
tients, and GWASs clearly indicate that there are no domi­
nant causative genes. However, the characteristic pathological 
features of the condition are suggestive of a common cellular 
pathology produced by the various additive molecular aetiol­
ogies. The neutrophils themselves appear functionally normal 
(Moráin et al., 1981), and their diminished migration to acute 
inflammatory sites in the skin or bowel has been attributed to 
defective local cytokine production (Marks et al., 2006). These 
mediators are primarily secreted by resident tissue macro­
phages (Medzhitov, 2008), which, in the bowel, are derived 
and continually replenished from peripheral blood mono­
cytes (Smythies et al., 2006). We therefore measured the se­JEM VOL. 206, August 31, 2009 
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Failure to clear foreign material from the tissues induces a 
chronic granulomatous reaction around the retained organic 
material over a much longer time frame. The accumulation of 
macrophages and T lymphocytes in these granulomata leads to 
local tissue damage and constitutional symptoms through the 
sustained secretion of cytokines (Bazzoni and Beutler, 1996). 
Even if the net production of cytokines by each cell were 
lower than normal, the overall number of cells is so great that 
damaging concentrations are produced. In this setting, drugs 
directed against TNF can prove beneficial by direct cytokine 
blockade, by inducing leukocyte apoptosis, and by stimulating 
the effect of Treg cells, which suppress inflammation (Wong   
et al., 2008). A clear example of the dichotomous effect of TNF 
is provided by the dextran sodium sulfate (DSS) bowel inflam­
mation model in TNF knock­out mice. Contrary to initial 
expectations, mice deficient in this cytokine are more suscep­
tible to the induction of bowel inflammation by DSS, whereas 
TNF inhibition is effective in ameliorating established DSS 
colitis in wild­type animals (Naito et al., 2003).
The relationship of impaired cytokine secretion to disor­
dered packaging and vesicle transport, rather than defects in 
their production or stability, provides a novel insight into the 
mechanisms underlying the pathogenesis of CD. Similar 
mechanisms could lead to abnormalities in other relevant cell 
types, such as the Paneth cell (Cadwell et al., 2008). A basic 
abnormality in macrophage biology could also explain ex­
traintestinal manifestations of CD, such as arthritis, and le­
sions in the eyes, skin, lungs, and other tissues (Ephgrave, 2007). 
There may be many other diseases that present with exuber­
ant granulomatous inflammation as a result of an underlying 
failure of acute inflammation and innate immunity, leading 
to defective clearance of the initiating agent.
MATERIALS AND METHODS
Patients. These studies were approved by the Joint University College Lon­
don (UCL)/UCL Hospitals (UCLH) Committee for the Ethics of Human 
Research (project numbers 02/0324 and 04/Q0502/29) and the Administra­
tion of Radioactive Substances Advisory Committee (RPC597­790). Patients 
from the Gastroenterology outpatient clinic at UCLH who met inclusion cri­
teria were recruited to participate in the study. All patients had definitive diag­
noses of CD or UC, which were confirmed using standard diagnostic criteria, 
with quiescent disease (Harvey­Bradshaw or Mayo score <3; Harvey and 
Bradshaw, 1980; Schroeder et al., 1987). Patients on either no medication or 
a stable maintenance dose of 5­aminosalicylates (2.5 g/d) for the previous 3 mo 
were included. None of the patients had received corticosteroid, immunosup­
pressant, anti­TNF, or metronidazole therapy within 3 mo of enrollment. HC 
subjects approximately matched for age, sex, and smoking history were re­
cruited from the Department of Medicine, UCL. Written informed consent 
was obtained from all volunteers. No subject was studied more than once in 
each of the different experiments. Details of patients and HC subjects included 
in in vivo experiments are provided (Table S4). CD patients were genotyped 
for the three common polymorphisms in CARD15 as previously described 
(Table S4; Marks et al., 2006). In some studies, we compared the results ob­
tained from CD patients with ileal or colonic involvement, as there is evidence 
that different pathogenic mechanisms might operate in these regions of the 
bowel (Cuthbert et al., 2002). We excluded the 30% of CD patients with 
mixed ileocolonic disease to simplify phenotyping and analysis.
Neutrophil accumulation studies. Details of controls and patients are pro­
vided in Table S4. No patient had received corticosteroid, immunosuppressant, 
that CD results from a failure to digest and remove microbial 
and other foreign material.
Interestingly, there was no other direct relationship be­
tween the collections of genes identified in this study in mac­
rophages and the polymorphisms highlighted by the previous 
GWAS (Wellcome Trust Case Control Consortium, 2007; 
Barrett et al., 2008), with the exception of HLA­G and SPTLC2, 
which were up­regulated and down­regulated, respectively, 
in colonic CD (Table S3). This is not entirely unexpected 
because association studies interrogate the whole genome in 
a nonselective manner, whereas we have focused on RNA 
expression in a single cell type, which plays a pivotal role in 
inflammation, in resting cells and those after activation with 
a naturally occurring agonist.
Several microarray expression studies have previously been 
performed in CD and UC. However, their experimental ap­
proach differed greatly from ours, as did the results they ob­
tained. This is not surprising in view of the very diverse cell 
populations and variable states of stimulation in their samples. 
Those on blood cells were performed on freshly isolated un­
stimulated mixed cell populations consisting of lymphocytes 
and monocytes with granulocyte contamination (Mannick   
et al., 2004; Burczynski et al., 2006). The majority used bowel 
biopsies, in which a wide spectrum of cells is present in non­
inflamed tissue. These are further supplemented by innate 
and adaptive immune cells when inflammation is present 
(Lawrance et al., 2001; Costello et al., 2005; Hughes, 2005).
To understand the failure of macrophages to secrete nor­
mal quantities of proinflammatory cytokines in CD, we used 
TNF as a model, because this molecule has been extensively 
studied and experimental tools are readily available. We found 
that gene transcription and mRNA stability are normal in CD 
macrophages. Bref­A prevents vesicular movement between 
the ER and the Golgi, resulting in accumulation of proteins 
within the former. Stimulation in the presence of Bref­A   
revealed normal cytokine synthesis by CD macrophages. Normal 
synthesis coupled with deficient secretion and low intracellu­
lar levels of the cytokines indicate accelerated degradation. 
The accumulation of normal amounts of TNF and other pro­
inflammatory cytokines after the addition of lysosomal inhib­
itors to CD cells indicates that this aberrant breakdown occurs 
in the lysosomal compartment.
The observation that macrophage secretion of TNF in 
CD is abnormally low might at first seem paradoxical, given 
the therapeutic efficacy of TNF blockade in many of these 
patients (van Deventer, 1999). However, we are comparing 
two temporally distinct events, acute inflammation over a 
time course of hours with chronic inflammation over weeks 
to months. The acute inflammatory response, dependent on 
the acute release of proinflammatory cytokines, is important 
for the clearance of bacteria and fecal material from the tis­
sues, which takes place over a few hours. The lack of TNF after 
the administration of therapeutic antagonists for the treatment 
of other chronic inflammatory diseases has been reported to 
precipitate the development of CD (Charach et al., 2008; 
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If a biological half­life of 3 h was presumed, the absorbed dose was estimated 
at 0.5–10.0 mGy.
The threshold dose of 32P resulting in erythema after extravasation has 
been determined as 10 Gy (Castronovo et al., 1988). A dose of 1 kBq was 
therefore selected as producing sufficient emitted radioactivity to be record­
able at the skin surface but falling well within acceptable established safety 
limits and ensuring that inflammation generated was solely the result of the 
presence of bacteria rather than isotope.
Macrophage isolation and culture and stimulation. Peripheral venous 
blood was collected from subjects into syringes containing 5 U/ml heparin. 
Mononuclear cells were isolated by differential centrifugation (900 g for 30 min 
at 20°C) over Lymphoprep and washed twice with sterile PBS (Invitrogen) at 
300 g (5 min at 20°C). Cells were resuspended in 10 ml RPMI­1640 medium 
(Invitrogen) supplemented with 100 U/ml of penicillin (Invitrogen), 100 µg/ml 
streptomycin (Invitrogen), and 20 mM Hepes, pH 7.4 (Sigma­Aldrich) and 
plated at a density of 5 × 106 cells/ml in 8 cm2 Nunclon Surface tissue culture 
dishes (Nunc) at 37°C in 5% CO2. After 2 h, nonadherent cells were discarded 
and 10 ml of fresh RPMI supplemented with 10% FBS (Sigma­Aldrich) was 
added to each tissue culture dish. Cells were then cultured for 5 d at 37°C in 5% 
CO2, with the addition of a further 10 ml of fresh 10% FBS/RPMI after 24 h.
Adherent cells were scraped on day 5 and replated in 96­well culture 
plates (Nunc) at equal densities (105/well) in X­Vivo­15 medium (Cambrex). 
These primary monocyte­derived macrophages were incubated overnight at 
37°C in 5% CO2 to adhere and were then stimulated for up to 24 h, depend­
ing on the experiment, with 2.5 × 105 HkEc, prepared as previously de­
scribed (Marks et al., 2006), 2 µg/ml Pam3CSK4 (Enzo Biochem, Inc.), or 
200 ng/ml LPS (Enzo Biochem, Inc.).
Cytokine secretion assays. Macrophage supernatants were collected after 
24­h stimulation of primary monocyte­derived macrophages with HkEc as 
described in the preceding section. The expression profile of a panel of cyto­
kines in macrophage supernatants was measured using the Beadlyte Bio­Plex 
human cytokine assay (Bio­Rad Laboratories) according to the manufactur­
er’s instructions. Our assay was customized to detect and quantify IL­1Ra, 
IL­4, IL­5, IL­6, IL­10, IL­12, IL­13, IL­15, IL­17, G­CSF, GM­CSF, 
IFN­, IP­10, and MCP­1. IL­8 secretion was measured using an ELISA kit 
(R&D Systems). The assay was conducted according to the manufacturers’ 
instructions with recombinant human standards.
TNF release was measured using a cytotoxicity bioassay (obtained from 
B. Beutler, The Scripps Institute, La Jolla, CA) as previously described (Aggarwal 
et al., 1985). Mouse L929 fibroblast cells were grown in DME (Invitrogen), 
supplemented with 10% FBS (Sigma­ALdrich), 100 U/ml of penicillin (In­
vitrogen), and 100 µg/ml streptomycin (Invitrogen) at 37°C in 5% CO2. A 
confluent monolayer of mouse L929 fibroblasts was trypsinized and resus­
pended to 4 × 105 cells/ml in DME. L929 cells were seeded into 96­well flat 
bottomed tissue culture plates (4 × 104 cells/well) and incubated overnight 
at 37°C in 5% CO2. After overnight culture, the medium was discarded, re­
placed by 50 µl DME containing 0.04 mg/ml cyclohexamide, and incubated 
for 20 min at 37°C in 5% CO2. 50 µl of cell­free supernatant (diluted 1:50 in 
DME), collected from primary macrophages as already described, were added 
to individual wells. Serially diluted recombinant human TNF (100–0 pg/ml; 
R&D Systems) was used to determine the standard curve for the assay.
Cytokine release in culture supernatants was normalized for the numbers 
of viable cells in each well, ascertained with the MTT (3­[4,5­dimethylthiazol­
2­yl]­2,5­diphenyl tetrazolium bromide, tetrazolium salt) assay (Boehringer 
Ingelheim). 20 µl of 2.5 ng/ml MTT was added to each well and incubated for 
4 h at 37°C in 5% CO2. Supernatants were carefully discarded and 100 µl/well 
of lysis solution (90% isopropanol, 0.5% SDS, 0.04 N HCl, and 10% H2O) was 
added to each well for 1 h at room temperature. The absorbance was read at 
570 nm using a microplate reader (Anthos Labtec Instruments).
RNA  purification.  Total  RNA  was  prepared  from  monocyte­derived 
macrophages, either unstimulated or stimulated for 4 h with HkEc, using the 
RNeasy Mini kit with RNase­free DNase treatment (QIAGEN). Optical 
anti­TNF, or nonsteroidal drug therapy within 3 mo of enrolling in the study, 
although patients on maintenance 5­aminosalicylates with no change in their 
dose in the previous 3 mo were included. Patients with a history of skin disease 
were not enrolled for any injection studies.
A fully antibiotic­sensitive clinical isolate of E. coli (NCTC 10418) was 
grown overnight at 37°C in DME (Sigma­ALdrich) and 1.25 g/liter sterile 
yeast extract (Oxoid). Bacteria were then killed by exposure to a UV source 
(ChemiDoc, trans­UV mode; Bio­Rad Laboratories) for 60 min, and washed 
multiple times in sterile saline. Bacterial concentrations were determined by 
optical density (OD600 = 0.365 equates to 108 E. coli/ml [Yourassowsky et al., 
1989]). Sterility of the final sample was confirmed by multiple cultures.
Peripheral venous blood was collected from subjects into syringes contain­
ing 5 U/ml heparin. Separate blood samples were taken for full blood count 
and routine serum biochemistry. Neutrophils were isolated by centrifugation 
through Lymphoprep (Axis Shield), and then erythrocytes were removed by 
sedimentation with 10% dextran followed by hypotonic lysis. The neutrophils 
were then washed once in sterile injection­grade normal saline and incubated 
with 6 MBq 111In­oxine (GE Healthcare) for 20 min at room temperature   
(Segal et al., 1981). A mean ± SEM of 3.40 ± 0.35 × 107 cells labeled with 
5.15 ± 0.17 MBq (n = 11) were resuspended in 5 ml of normal saline. These 
were injected intravenously through a cannula in a vein in the antecubital fossa, 
which was subsequently flushed with a further 10 ml of normal saline.
Immediately after neutrophil injection, 3 × 107 UV­killed E. coli sus­
pended in 100 µl of normal saline were injected subcutaneously into the volar 
aspect of each forearm. Radioactivity was counted using a  counter in scaler 
mode (RadEye B20; Thermo Fisher Scientific) over these injection sites at 
baseline and at 1, 4, and 24 h after injection. These sites were shielded from 
the remainder of the body during counting to avoid detection of label accu­
mulating in the liver or spleen. To control for background radioactivity, this 
was counted over a control site in the left calf and these counts were sub­
tracted from counts over the injection sites to obtain specific accumulations 
of radioactivity produced by the bacterial injections. The absolute radioactiv­
ity at the injection sites was determined by calibration of the meter against se­
rial dilutions of a sample of free 111In­oxine with known activity. The 24­h 
counts over the injection sites in the six HC subjects were 1,738 ± 98 cpm. 
We did not study control subjects with UC because we felt that the addi­
tional information we would obtain did not justify the theoretical risk of ad­
ministering radioactivity systemically to these subjects.
Bacterial clearance studies. Details of controls and patients included in each 
set of experiments are provided in Table S4. E. coli were grown, as before, 
overnight at 37°C in 9 ml of phosphate­free DME (Invitrogen) supplemented 
with 1 ml of phosphate­containing DME (Sigma­Aldrich), 1.25 g/liter of ster­
ile yeast extract, and 18.5 MBq 32P­orthophosphate PBS (GE Healthcare). This 
isotope was chosen because it is a  emitter with a short half­life (14.7 d) but 
of sufficient energy to emit through skin and readily and stably incorporate into 
bacteria (Jordan, 1970). Labeled bacteria were killed by UV exposure for 60 
min and washed multiple times in sterile saline to remove unbound radiolabel. 
A specific activity ± SEM of 6.39 ± 1.52 MBq per 108 bacteria was achieved. 
Unlabeled bacteria from the same reference sample were also grown and killed 
by UV exposure for 60 min, in the absence of radiolabel and in phosphate­
containing DME supplemented with sterile yeast extract.
A preparation of E. coli containing 1 kBq of radioactivity was mixed 
with unlabeled bacteria to produce a dose range of 105, 106, 107, 3 × 107, and 
108 bacteria in 100 µl of sterile saline for inoculation (different doses were 
used depending on the experiment) and injected into the volar aspect of 
both forearms. Surface radioactivity was counted over a 3­min period using 
a  counter in scaler mode (RadEye B203). Initial surface counts per minute 
at each site were 2,688 ± 160 (mean ± SEM). Counts were subsequently re­
peated at 4, 24, 48, and 72 h. Correlations between the readings in each arm 
were r2 = 0.67 (P < 0.005).
Radiation dose in bacterial clearance studies. Using values published 
for 32P in the MIRDOSE 3.1 spherical tumor model (Stabin, 1996), with a 
presumed tissue dispersion volume of 0.1–3.9 ml, a dose of 1 kBq was calcu­
lated to deliver an absorbed dose of 0.06–1.00 Gy if no clearance occurred. JEM VOL. 206, August 31, 2009 
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GGGC­3). The final optimized concentrations for the forward and reverse 
primers plus the probe were 900 nmol/l, 900 nmol/liter and 100 nmol/liter, 
respectively. A standard curve was generated using human genomic DNA 
(Promega). PCR parameters were the following: 50°C for 2 min, 95°C for 
10 min, 40 cycles of 95°C for 15 s, and 60°C for 1 min. Data were acquired 
and processed with Sequence Detector 2.3 software (Applied Biosystems). A 
linear regression line calculated from the standard curves of serially diluted 
genomic DNA allowed relative transcript levels in RNA­derived cDNA 
samples to be calculated from the fluorescent signal in each run.
The data generated by the real­time PCR TaqMan were analyzed in 
Array Studio. The genes selected for RT­PCR were normalized using a co­
variate to account for any change in expression caused by RNA loading of the 
samples. This covariate was represented by the scores from the first principal 
component obtained from a PCA of the two housekeepers, ­actin and cy­
clophilin­, and 2­microglobulin (identified from the microarray data analy­
ses as having invariant expression across all samples). A general linear model 
was built to look at the comparisons of HCs versus each disease group by treat­
ment, and unstimulated versus stimulated samples by disease group. An FDR 
correction was applied using the Benjamini and Hochberg (1995) methods.
TNF reporter studies. Recombinant replication­deficient adenoviral con­
structs encoding pAdTrack­TNF 5 promoter­luciferase­3 UTR (AdTNF 
5/3) and pAdTrack­TRF 5 promoter­luciferase (AdTNF 5 only) were 
generated  as  previously  described  (Horwood  et  al.,  2003).  Macrophages 
were plated in 96­well plates (Nunc) at 105 cells/well and allowed to express 
adenoviral transgenes for 24 h before stimulation with HkEc for 4 h. Lucif­
erase reporter gene assays were performed as previously described (Palmer   
et al., 2008). Before lysis, viral infection rates were measured by GFP fluo­
rescence (excitation, 485 nm; emission, 520 nm) using a FLUOstar Omega 
machine (BMG LABTECH) and software according the manufacturer’s in­
structions, and luciferase activity was normalized to these levels.
mRNA stability. Macrophages were stimulated with HkEc for 4 h fol­
lowed by the addition of 2 µg/ml actinomycin D. Total RNA was purified 
as described in RNA purification at 0, 1, 2, and 4 h. TNF mRNA levels 
were determined by RT quantitative PCR and normalized to GAPDH and 
ribosomal 18S.
Cytokine  protein  arrays.  5  ×  105  macrophages  were  incubated  with 
HkEc alone or in combination with 2.5 µM Bref­A (Merck) or 2.5 µM mo­
nensin (Sigma­Aldrich) for 4 h. Cells were lysed in TBS containing 0.1% 
NP­40 and protease inhibitors, sonicated (3× 3­s bursts), and then interro­
gated with commercially available antibody arrays (Human Cytokine Array 
Panel A; R&D Systems), according to the manufacturer’s instructions. Pro­
cessed arrays were exposed to x­ray film, and the signal was determined and 
normalized to the internal positive control spots by densitometry using Im­
ageJ software (National Institutes of Health).
Lysosomal inhibition and cytokine production. 2 × 105 macrophages 
from patients with CD and HC subjects were prepared as previously de­
scribed and stimulated for 4 h with 5 × 105 HkEc plus either cell media, or 
media with 2.5 µM monensin, 10 mM NH4Cl, or 100 µM chloroquine. 
Macrophages were lysed and run on 10% tricine PAGE gel followed by 
Western blotting. Membranes were incubated with goat anti­TNF (R&D 
Systems) 1:1,500 overnight at 4°C. After washing, the membranes were in­
cubated with anti–goat­HRP (Vector Laboratories) at 1:2,000 for 1 h at room 
temperature, washed again, and then visualized with ECL plus detection re­
agent (GE Healthcare). All gels were subjected to ImageJ software analysis 
and normalized to actin.
Online supplemental material. Fig. S1 shows bacterial clearance in CD and 
HC subjects subdivided according to disease phenotype and CARD15 geno­
type. Fig. S2 shows macrophage cytokine release after 24­h stimulation with 
TLR2 and TLR4 ligands. Fig. S3 depicts macrophage phenotype analysis. 
Fig. S4 shows functional groupings of the most significantly up­regulated 
density readings were determined for OD260/OD280 and OD260/OD230 using 
a NanoDrop ND­1000 spectrophotometer (Thermo Fisher Scientific) to as­
sess protein and solvent contamination, respectively. Before GeneChip stud­
ies, RNA quality was further analyzed by assessing ribosomal RNA bands 
28S/18S ratios using a Bioanalyzer (Agilent Technologies) high resolution 
electrophoresis system.
Whole genome GeneChip expression analysis. RNA samples were an­
onymized and randomized by disease group, treatment, and gender into 
three balanced batches. Linear amplification of RNA samples was performed 
using the standard Ovation RNA Amplification System 2 (NuGEN) as one 
batch on two 96­well plates. Samples were then fragmented, biotin labeled, 
and hybridized in three separate batches to the human U133 plus 2 GeneChip 
(Affymetrix) for 16 h to generate the transcriptomic data. The microarrays 
were washed and scanned according to Affymetrix protocols. Quality was 
assessed using report files generated in GCOS (GeneChip Operating System; 
Affymetrix) and checked against in­house criteria (GlaxoSmithKline) for 
probe and hybridization quality by analysis of the data for background, per­
centage of present calls, background standard deviation, raw Q (noise), scal­
ing factor, GAPDH 3 to 5 ratio, and ­actin 3 to 5 ratio (Heber and Sick, 
2006). The data were assessed for homogeneity of quality control metrics by 
principal component analysis (PCA) of gene expression using Array Studio 
(OmicSoft Corporation). To ensure that all samples corresponded to the an­
notated gender, expression was analyzed for gender­specific genes (XIST 
and USP9Y). Data from a total of 66 microarrays were therefore analyzed: 
HC, 16 unstimulated and 12 HkEc; ileal CD, 9 unstimulated and 6 HkEC; 
and colonic CD, 13 unstimulated and 10 HkEc. Global gene expression of 
the normalized probe intensity data were initially analyzed using Array Stu­
dio for the visual assessment of key trends by PCA. Further analysis of the 
intensities used a General Linear Model (GLM) performed in Array Studio. 
The GLM was used to build comparisons of HCs versus each disease group 
by treatment. A second experiment was then performed in which compari­
sons were made between macrophages from HC (7 unstimulated and   
5 HkEc) and UC (19 unstimulated and 20 HkEc). Genes were considered to 
be differentially expressed between groups where P < 0.01, fold change was 
≥1.2, and expression level was greater than the median cut of 5.0 fluores­
cence units. Where appropriate, the p­value was corrected for multiple 
comparisons (FDR correction, Benjamini and Hochberg [1995] method). 
For the overlaps of the Venn diagrams where a significant result was ob­
tained independently in two separate experiments, the FDR correction was 
not applied; for assessment of the most significantly regulated genes, both 
raw p­value and FDR­corrected p­value are presented. Microarray data in 
MIAME format can be found at http://www.ebi.ac.uk/microarray­as/ae/ 
under accession nos. E­TABM­733 and E­TABM­734.
TaqMan protocol. Expression levels of selected genes found to be differ­
entially regulated by the transcriptomic array data were validated by real­time 
RT­PCR TaqMan analysis using the ABI Prism 7900 Sequence Detector 
System (Applied Biosystems). 200 ng of total RNA were reverse transcribed 
to complementary DNA (cDNA) using the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems) according to the standard protocol. 
The equivalent of 10 ng RNA per well was arrayed into 384­well plates using 
a Biomek FX robot (Beckman Coulter), and quantitative RT­PCR was 
performed using a 7900HT Sequence Detector System (Applied Biosystems) 
in a 10­µl reaction volume.
The following TaqMan primers and probes used: GMCSF (forward, 
5­AGCCTCACCAAGCTCAAGGG­3;  reverse,  5­GGGTTGGAGG­
GCAGTGCT­3;  probe,  5­CCCTTGACCATGATGGCCAGCC­3), 
IL6 (forward, 5­TGACCCAACCACAAATGCCA­3; reverse, 5­CAT­
GTCCTGCAGCCACTGG­3;  probe,  5­CTGTGCCTGCAGCTTC­
GTCAGCA­3),  IFN­  (forward,  5­CCAACGCAAAGCAATACAT­
GAAC­3; reverse, 5­ACCTCGAAACAGCATCTGACTCC­3; probe, 
5­TCATCCAAGTGATGGCTGAACTGTCGC­3), and TNF (forward, 
5­TCCTCTCTGCCATCAAGAGCC­3; reverse, 5­GTCGGTCACCC­
TTCTCCAGC­3;  probe,  5­TGGAAGACCCCTCCCAGATAGAT­1896 INFLAMMATION AND MACROPHAGES IN CROHN’S | Smith et al.
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